Spago Nanomedical recently completed its rights issue fundraising round in a rights issue, saying it will raise about 58.4 million Swedish krona (5.4 million euros) before deduction of costs.
The company said the rights issue has been subscribed for about 94.6%, with 60.5% subscribed for with and without the exercise of subscription rights, and the other 34.1% subscribed for by guarantors.
Spago said funds raised will go toward beginning the clinical phase I/IIa-study for its lutetium-177-based radiopharmaceutical candidate 177Lu-SN201, planned to start in 2022.
